Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903935 | 0.83 | CYP2D6 (0.60) | CYP2D6MAPTLMNAGSK3BMAP4K4 | |
| SCHEMBL6852363 | 0.81 | CYP2D6 (0.51) | CYP2D6MAPTGSK3BMAP4K4EGFR | |
| SCHEMBL24791663 | 0.81 | CYP2D6 (0.51) | CYP2D6MAPTGSK3BMAPK9CYP11B1 | |
| SCHEMBL2559714 | 0.81 | CYP2D6 (0.51) | CYP2D6MAPTALDH1A1GSK3BMAP4K4 | |
| SCHEMBL30872067 | 0.81 | CYP2D6 (0.51) | CYP2D6MAPTGSK3BMAPK9CYP11B1 | |
| SCHEMBL29415422 | 0.80 | CYP2D6 (0.55) | CYP2D6NPC1MAPTSMN1; SMN2GSK3B | |
| SCHEMBL13625499 | 0.80 | CYP2D6 (0.51) | CYP2D6MAPTGSK3BMAP4K4EGFR | |
| SCHEMBL28848117 | 0.79 | HRH3 (0.52) | CYP2D6MAPTMAPK9CYP11B1CYP11B2 | |
| SCHEMBL13675153 | 0.79 | IDO1 (0.50) | CYP2D6GSK3BNISCHMAPK9 | |
| SCHEMBL1445174 | 0.78 | CYP2D6 (0.76) | CYP2D6RAB9ANPC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653621-A1 | APPARATUS FOR SYNTHESIZING THE IMAGING AGENT 4-CHLORO-2-(1,1-DIMETHYLETHYL)-5-[[4-[[2-(FLUORO-[18F])ETHOXY]METHYL]PHENYL]METHOXY]-3(2H)-PYRIDAZINONE (FLUORPIRIDAZ [18F]) | Lantheus Medical Imaging, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-2882719-B1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS IMAGING AGENTS FOR DETECTING MYOCARDIAL PERFUSION | LANTHEUS MEDICAL IMAGING INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | CYP2D6 61/4885METAP2 2409/4885RAB9A 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.